Aankondiging • Jun 30
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 29, 2026 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 29, 2026 Aankondiging • Jan 30
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2025 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided earnings guidance for the year ended December 31, 2025. for the year, Net profit attributable to shareholders of the listed company of RMB 284.00 million to RMB 377.00 million . Basic earnings per share of RMB 0.1936 per share to RMB 0.2569 per share. reasons for changes in the results: During the Reporting Period, the Group achieved significant progress in expanding its global heparin finished dose business. Sales performance across all regions showed steady growth, with market share continuing to increase. Sales volume of enoxaparin finished dose achieved double-digit growth, further solidifying the Group's global competitive position. During the Reporting Period, the Company's net profit attributable to shareholders of the listed company decreased year-on-year. This was primarily due to a high base formed by non-recurring profit or loss from a one-time investment income exceeding RMB 350 million in the corresponding period of last year. Additionally, an associate company of the Company is expected to have a certain impact on the Group's net profit due to its research and development progress falling short of expectations. The specific impact is subject to final confirmation by the accounting firm. Net profit attributable to shareholders of the listed company (after non-recurring profit or loss) increased as compared with the corresponding period of last year during the Reporting Period, primarily driven by steady growth in core business revenue and profits. Concurrently, the Company continued to enhance operational efficiency and drive sustained profitability improvements through strengthened financial management and optimized resource allocation. Although the associate company is expected to have a certain impact on the Group's net profit (after non-recurring profit or loss), the Group still achieved steady growth in net profit (after non-recurring profit or loss), demonstrating its operational resilience and sustained growth capability of its core business. Aankondiging • Dec 31
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026 Aankondiging • Sep 30
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Aankondiging • Jul 18
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Completes the First Subject and the First Dosing in the Phase 1 Clinical Trial Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that the Company has recently completed the enrollment of the first subject and the first dosing in the phase I clinical trial of its independently developed innovative candidate drug, the H1710 injection. In February 2025, the Company received the Notice of Approval for Clinical Trial issued by the National Medical Products Administration for approving the clinical trial of the H1710 injection.
This clinical trial is an open-label, dose-escalation Phase Ia clinical study, evaluating the safety, tolerability and preliminary anti-tumor activity of H1710 in patients with advanced solid tumors. This is the first in-human trial for H1710, which is planned to be conducted at three research centers, with an estimated enrollment of about 36 patients. H1710 is an innovative drug targeting heparanase for the treatment of advanced solid tumors. To the best knowledge of the Company, as of the date of this announcement, there are no products with the same molecular mechanism that have been approved for marketing anywhere in the world. Aankondiging • Jul 02
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025 Aankondiging • Feb 18
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Receives the Notice of Approval for Clinical Trial Issued by the National Medical Products Administration for Approving the H1710 Injection Shenzhen Hepalink Pharmaceutical Group Co., Ltd. board of directors announced that the Company has recently received the Notice of Approval for Clinical Trial issued by the National Medical Products Administration ("NMPA") for approving the H1710 injection ("H1710"). Relevant information is as follows. Drug Name: H1710 injection. Indications: Advanced solid tumor. Registration Classification: Class 1 chemical drug. Application Matter: Clinical trial. Applicant: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Review Conclusions: According to the Drug Administration Law of the People's Republic of China and relevant regulations, upon review, the investigational new drug application for the H1710 injection accepted on December 3, 2024 meets the relevant requirements for drug registration, and this drug has been approved to conduct clinical trials as monotherapy for the treatment of advanced solid tumors H1710 is a candidate drug independently developed by the Company, and the Company owns the global rights to develop and commercialize H1710. H1710 is a novel compound that targets heparanase, a heparin-degrading enzyme. It has a suitable chain length and a unique flexible structure, and competitively binds to heparanase with heparan sulfate proteoglycans or heparin, making it a highly efficient and selective heparanase inhibitor. Heparanase is overexpressed in various tumors and is associated with tumor growth and metastasis. Studies have shown that targeting heparanase is a new anticancer strategy. The Company's preclinical research has demonstrated that H1710 exhibits anti-tumor pharmacological activity by inhibiting the activity and expression of heparanase. H1710 has shown significant anti-tumor effects in various tumor animal models. As at the date of this announcement, there is no similar product with the same molecular mechanism on the market worldwide. According to the relevant laws and regulations related to national drug registration, drugs are required to conduct clinical trials and obtain relevant data after receiving the Notice of Approval for Clinical Trial, and can only be marketed after being approved by the NMPA. Since clinical research involves a long cycle, high investment and many unpredictable factors during the process, there are many uncertainties regarding the results and time of clinical trials, review and approval. The Company will fulfill its information disclosure obligations in a timely manner for subsequent development progress. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company. Aankondiging • Dec 31
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Mar 29, 2025 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Mar 29, 2025 Aankondiging • Sep 30
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Aankondiging • Jun 29
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024 Aankondiging • Mar 30
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Aankondiging • Dec 30
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Mar 29, 2024 Aankondiging • Aug 22
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Change of Financial Controller from Mr. Xiang Xianqing to Ms. Chen Juan Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced change of financial controller from Mr. Xiang Xianqing to Ms. Chen Juan with effect from August 21, 2023. Ms. Chen, 48, is a seasoned financial manager with more than 20 years of financial management experience in large multinational companies. She obtained a bachelor's degree in economics from Hubei University and received a master's degree in accounting from Tsinghua University. She also holds a licence as a Chartered Global Management Accountant and is a member of Institute of Public Accountants. From 2012 to 2015, she served as the financial director of IBM System Technology (Shenzhen) Co., Ltd. and Lenovo System Technology (Shenzhen) Co., Ltd.; from 2016 to 2017, she served as the head of internal control of the hardware system maintenance division of IBM Greater China; from 2017 to 2022, she was the person-in-charge of SF Express Group customer settlement center; from 2022 to 2023, she was the financial controller of SF Airlines; she joined Hepalink in August 2023. Aankondiging • Jul 12
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on July 18, 2023 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced final cash dividend of CNY 1.00 per 10 shares on A shares for the year 2022. Record date is July 17, 2023, Ex-Date is July 18, 2023 and Payment Date is July 18, 2023. Aankondiging • May 26
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2022 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. at its Annual General Meeting held on 22 May 2023 approved cash dividend of CNY 1.00000000 per 10 shares (tax included) for 2022. Aankondiging • Jan 31
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2022. For the year ending December 31, 2022, the company expects net profit attributable to shareholders of the listed company of RMB 617.00 million to RMB 773.00 million, increase as compared with the corresponding period: 156.24% to 221.03% and basic earnings per share of RMB 0.4205 per share to RMB 0.5268 per share. 
